ArticleChinese journal of integrative medicine2026
Efficacy and Safety of Zizhu Ointment for Wagner Grade 2 Diabetic Foot Ulcers: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Trial.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical efficacy and safety of Zizhu Ointment (ZZO) in treating Wagner grade 2 diabetic foot ulcers (DFUs).
methodsIn this single-center, randomized, double-blind, placebo-controlled trial, using SPSS 26.0, a computer-generated random number sequence was used to randomly assign 154 patients with Wagner grade 2 DFUs in a 1:1 ratio to either the ZZO group (n=77) or the placebo control group (n=77). Both groups received conventional therapy and standard debridement. Patients received the assigned intervention as a topical application for 6 weeks, followed by a 6-week follow-up period. The primary outcome was the ulcer healing rate at 6 weeks. Secondary outcomes included Chinese medicine (CM) syndrome scores, transcutaneous oxygen pressure (TcPO
resultsAfter 6 weeks, the ulcer healing rate was significantly higher in the ZZO group than in the placebo control group (67.59% ± 22.69% vs. 28.81% ± 15.80%, P<0.001). This superiority was maintained at the end of the 6-week follow-up (80.95% ±19.16% vs. 42.20% ±21.93%, P<0.001). The ZZO group also demonstrated significantly greater improvements in reducing ulcer area and depth, improving CM syndrome scores, TcPO
conclusionsZZO effectively promotes the healing of Wagner grade 2 DFUs, ameliorates the wound microenvironment and CM symptoms, and exhibits a favorable safety profile. (Registration No. ITMCTR2025000126).
Indexed as
Identifiers
42518111What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.